Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

NCT00250640

Hypertension, Pulmonary

COMPLETED

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

NCT02825160

Hypertension, Pulmonary

COMPLETED

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

NCT00185315

Hypertension, Pulmonary

COMPLETED PHASE3

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

NCT01389271

Pulmonary Hypertension

COMPLETED

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

NCT01062282

Pulmonary Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Ventavis (Iloprost, BAYQ6256)

Intervention Type DRUG

Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ventavis (Iloprost, BAYQ6256)

Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both male and female age 18-65 years old
* The treating physician has chosen Ventavis as a suitable long-term treatment for the patient
* Patient with Primary Pulmonary Hypertension (i.e. IPAH or FPAH) and classified as NYHA functional class III
* Written informed/data protection consent
* No prior treatment with Ventavis or other active treatments for PPH within 6 weeks of date of study.